Galectin Therapeutics Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Galectin Therapeutics Inc. (GALT) holds an ST Score of 61.9 out of 100 (B), with its strongest factor being Valuation (A+) and its weakest Financial Strength (C-). Analysts rate GALT Buy across 11 ratings with a $11.00 average price target (+1.8% vs the current $3.89).
- Strongest
- ValuationA+
- Weakest
- Financial StrengthC-
All factor grades
- ValuationA+
- ForecastA
- MomentumB+
- ProfitabilityB
- GrowthB
- Financial StrengthC-
- Piotroski2/9
Contact
GALT stock: frequently asked questions
What is GALT's ST Score?
Galectin Therapeutics Inc. (GALT) has an ST Score of 61.9 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is GALT a buy, sell, or hold?
Wall Street's consensus rating on GALT is Buy based on 11 analyst ratings. Our own ST Score grades it B (61.9/100). This is data, not investment advice — always do your own research.
What is GALT's valuation grade?
Galectin Therapeutics Inc. (GALT) earns a valuation grade of A+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is GALT's growth grade?
Galectin Therapeutics Inc. (GALT) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is GALT's profitability grade?
Galectin Therapeutics Inc. (GALT) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is GALT's financial strength grade?
Galectin Therapeutics Inc. (GALT) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for GALT?
The average analyst price target for Galectin Therapeutics Inc. (GALT) is $11.00 from 11 analysts, which is +1.8% versus the recent price of $3.89.
What is GALT's Piotroski score?
Galectin Therapeutics Inc. (GALT) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.